Literature DB >> 9863550

Association of the insertion/deletion gene polymorphism of the apolipoprotein B signal peptide with myocardial infarction.

A Gardemann1, D Ohly, M Fink, N Katz, H Tillmanns, F W Hehrlein, W Haberbosch.   

Abstract

The Del allele of the apolipoprotein B (apoB) signal peptide (SP) insertion/deletion (Ins/Del) polymorphism has been shown to be associated with elevated plasma levels of apoB, cholesterol and low density lipoprotein. It was the aim of the present study to analyse the relation of this gene variation to the risk of coronary artery disease (CAD) and of myocardial infarction (MI) in a population of 2259 male Caucasians, whose coronary anatomy was defined by means of coronary angiography. ApoB SP DelDel genotypes had significantly higher apoB plasma concentrations than InsIns homozygotes (P = 0.0001) and InsDel heterozygotes (P = 0.002); however, the apoB plasma levels of InsIns and InsDel genotypes were essentially the same (P = 0.54). Similar observations were made with respect to ApoB SP genotype-dependent cholesterol plasma concentrations. Since the apoB plasma level was not only associated with the apoB SP Ins/Del gene variation but also to the extent of coronary artery disease (P <0.0001), individuals with an InsIns genotype and without CAD had the lowest and subjects with a DelDel genotype and triple vessel disease the highest apoB plasma levels (P <0.0001). An association of the apoB SP Ins/Del gene variation with CAD was not detected, neither in the total population nor in low risk groups. In contrast, the gene variation was associated with MI (P <0.05). An Odds ratio of 1.18 (95% CI, 1.01-1.39) associated with the Del allele was detected in the total sample (P <0.02). In a subpopulation of individuals with low plasma triglyceride levels ( <154 mg/dl; mean value) and an DD genotype of the angiotensin I-converting enzyme insertion/deletion gene polymorphism an Odds ratio of 2.01 (1.42-3.05) was calculated (P <0.001). The present study presents evidence for a statistically significant difference in the development of MI between genotype classes of the apoB SP Ins/Del gene polymorphism.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9863550     DOI: 10.1016/s0021-9150(98)00161-0

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  6 in total

1.  Apo B gene haplotype is associated with lipid profile of higher risk for coronary heart disease in Caucasian Brazilian men.

Authors:  M O Machado; M H Hirata; M C Bertolami; R D Hirata
Journal:  J Clin Lab Anal       Date:  2001       Impact factor: 2.352

2.  Molecular variation at the apolipoprotein B gene locus in relation to lipids and cardiovascular disease: a systematic meta-analysis.

Authors:  S Matthijs Boekholdt; Ron J G Peters; Katerina Fountoulaki; John J P Kastelein; Eric J G Sijbrands
Journal:  Hum Genet       Date:  2003-08-26       Impact factor: 4.132

3.  Five polymorphisms in gene candidates for cardiovascular disease in Afro-Brazilian individuals.

Authors:  Tatsuya Sakuma; Rosario D C Hirata; Mario H Hirata
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

Review 4.  The roles of genetic polymorphisms and human immunodeficiency virus infection in lipid metabolism.

Authors:  Elaine Regina Delicato de Almeida; Edna Maria Vissoci Reiche; Ana Paula Kallaur; Tamires Flauzino; Maria Angelica Ehara Watanabe
Journal:  Biomed Res Int       Date:  2013-11-12       Impact factor: 3.411

5.  The APOB insertion/deletion polymorphism (rs17240441) influences postprandial lipaemia in healthy adults.

Authors:  Karani Santhanakrishnan Vimaleswaran; Anne M Minihane; Yue Li; Rosalyn Gill; Julie A Lovegrove; Christine M Williams; Kim G Jackson
Journal:  Nutr Metab (Lond)       Date:  2015-03-08       Impact factor: 4.169

6.  Associations of the APOB rs693 and rs17240441 polymorphisms with plasma APOB and lipid levels: a meta-analysis.

Authors:  Caiqin Niu; Zhi Luo; Liuqin Yu; Yang Yang; Yun Chen; Xin Luo; Feiya Lai; Yongyan Song
Journal:  Lipids Health Dis       Date:  2017-09-06       Impact factor: 3.876

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.